A 34-year-old man with a history of rectal cancer was receiving oral chemotherapy [tegafur-uracil (UFT) with leucovorin]. He visited our hospital due to nausea and abdominal pain, and his laboratory data revealed the presence of urinary ketones, hyperglycemia and high anion gap metabolic acidosis, and HbA1c level of 6.8%. Accordingly, we diagnosed fulminant type 1 diabetes. The development of fulminant type 1 diabetes during chemotherapy for malignancy is a rare, but potentially fatal condition. Therefore, clinicians should consider diabetic ketoacidosis in the differential diagnosis when examining chemotherapy patients who present with gastrointestinal symptoms.
Introduction
Fulminant type 1 diabetes is defined as a subtype of type 1 diabetes with rapid beta cell destruction. Clinically, it is characterized by the extremely rapid onset of severe hyperglycemia and ketoacidosis (1) . It has been suggested that viral infections lead to an immune reaction against infected beta cells, subsequently accelerating their destruction (2) . However, the incidence of fulminant type 1 diabetes during chemotherapy for malignancy is rare. We herein report the case of a patient who developed fulminant type 1 diabetes during chemotherapy for rectal cancer, and review the literature on this unusual entity.
Case Report
A 34-year-old man with a history of rectal cancer was admitted to our hospital for the treatment of hyperglycemia and ketoacidosis. Four years earlier, the patient had undergone rectal resection as treatment for rectal cancer. He had been taking oral anti-cancer agents [tegafur-uracil (UFT) with leucovorin] as adjuvant therapy since his surgery. Each chemotherapy cycle entailed the oral administration of UFT and leucovorin for 28 days, followed by a seven-day rest period. Ten days before admission, the patient had stopped taking UFT and leucovorin due to the scheduled resting period. He had been in his usual state of health until seven days prior to admission. Seven days before admission, he developed a high fever. The following day, he developed nausea and upper abdominal pain. Five days before admission, he developed severe thirst and polyuria. On the day of his admission, he visited the emergency department due to thirst and malaise.
The patient had no family history of diabetes mellitus, and had no history of impaired glucose tolerance during the time he had been undergoing chemotherapy. He drank alcohol occasionally and smoked half a packed of cigarettes daily. He had no known allergies and did not use illicit drugs or herbal remedies. On examination, the patient's blood pressure was 116/42 mmHg, his pulse was 100 beats/ min and his body temperature was 37.1 . He weighed 61 kg, his height was 169.5 cm and his body mass index (weight in kilograms divided by the square of the height in meters) was 21.2 kg/m 2 . He was alert but lethargic. There was abdominal tenderness in the right upper quadrant. The remaining findings of the neurological and general examinations were normal. Ketone bodies were detected on urinaly- sis. An arterial blood gas analysis showed high anion gap metabolic acidosis. The patient's biochemistry data revealed electrolyte disturbances and hyperglycemia.
On the day of his admission, the patient's plasma glucose level and HbA1c were 1,068 mg/dL and 6.8%, respectively. On the third hospital day, his fasting serum C-peptide level was 0.08 ng/mL (reference range 0.61-2.09 ng/mL). On the fifth hospital day, his urinary C-peptide level was 17.7 μg/ day (reference range 29.2-167 μg/day). On the patient's 14th hospital day, a glucagon stimulation test was performed, and showed no response with serum C-peptide excretion. These findings indicated severe impairment of insulin secretion. It was also found that the anti-glutamic acid antibody titer was low. He was negative for other autoantibodies. DNA typing revealed that the patient had a genetic susceptibility to fulminant type 1 diabetes (Table) . Taken together, our findings were compatible with a diagnosis of ketoacidosis due to fulminant type 1 diabetes mellitus. The patient was initially administered isotonic saline and a continuous insulin infusion. After resolution of the diabetic ketoacidosis, he was switched from continuous insulin infusion to multiple daily injections of insulin on the fourth hospital day. The patient's oral chemotherapy was discontinued. His HbA1c value never exceeded 7.0% one year after admission. Two years after admission, his anti-glutamic acid antibody titer became negative.
Discussion
Our clinical findings in this case were consistent with the diagnostic criteria for fulminant type 1 diabetes (1). Other findings, such as a low titer of antibodies to glutamic acid decarboxylase and elevated serum pancreatic enzyme levels, were also compatible with the diagnosis of fulminant type 1 diabetes. In Japan, fulminant type 1 diabetes constitutes 0.2% of all new-onset diabetes cases, and 14.8-19.6% of acute-onset type 1 diabetes cases (3, 4) . Flu-like symptoms or gastrointestinal symptoms precede the onset of the disease in 70% of patients (1) . The patient in the case discussed here also experienced gastrointestinal symptoms, specifically nausea and abdominal pain.
The pathogenesis of fulminant type 1 diabetes is influenced by genetic and environmental factors. Concerning genetic factors, human leukocyte antigen (HLA) class II genes are strongly associated with the susceptibility to the progression to fulminant type 1 diabetes. A haplotype analysis showed that DR4-DQ4 is significantly more common in individuals with fulminant type 1 diabetes (5) 03 :03 has been found to be more common in cases of fulminant type 1 diabetes in which antibodies to glutamic acid decarboxylase are present (6) . The present case is consistent with these previous findings. In addition, a non-HLA gene polymorphism, CTLA-4 CT60, has also been reported to be associated with fulminant type 1 diabetes (7). We did not perform genotyping for CTLA-4 in the present case.
With regard to environmental factors, viral infections may trigger a cytotoxic reaction to infected beta cells by activating lymphocytes and antigen-presenting cells (8) . In particular, enteroviral infection is related to the development of fulminant type 1 diabetes (9) and induces hyper-expression of pattern recognition receptors in beta cells. When pattern recognition receptors sense the enterovirus, genes involved in inflammatory responses are transcribed (10) . However, it is not clear whether an enterovirus played a role in the present case because we did not examine him for viral titers specific for this virus.
Anti-cancer agents might also act as an environmental factor inducing the onset of fulminant type 1 diabetes. Some studies have reported that the anti-cancer agent interferon alpha induced autoimmune-mediated type 1 diabetes (11, 12) . The exact role of interferon alpha in the onset of type 1 diabetes is unclear in humans, but it is known that interferon alpha promotes the maturation of conventional dendritic cells and the activation of B cells in mice, thereby leading to autoimmune diabetes. Interferon alpha also directly influences pancreatic beta cells by inducing cytokines and enhancing their susceptibility to invasion by diabetogenic T cells (13) . On the other hand, reports of fulminant type 1 diabetes induced by an anti-cancer agent are rare. There was one report of fulminant type 1 diabetes developing in a patient receiving paclitaxel; however, the pathogenesis of the fulminant type 1 diabetes in that case was unclear (14) .
UFT is an antineoplastic drug that combines tegafur and uracil (15) . Tegafur is a prodrug of 5-fluorouracil that is converted to 5-fluorouracil by hepatic metabolism. 5-fluorouracil exerts its antineoplastic effects through the inhibition of RNA synthesis by its active metabolites and through the action of thymidylate synthase (16) . Coadministration with uracil enhances the inhibition of 5-fluorouracil degradation, which results in increased concentrations of 5-fluorouracil (17) . UFT often causes neutropenia, stomatitis, hand-foot syndrome or alopecia, but diabetes is a rare complication. In the case discussed here, the patient never experienced neutropenia.
UFT might influence the development of fulminant type 1 diabetes through two possible mechanisms. The first of these is by means of immune suppression or an immunological reaction, and the second is through the effects of thymidine phosphorylase.
In the first case, UFT might affect the development of fulminant type 1 diabetes through immune suppression or an immunological reaction. At lower concentrations, 5-fluorouracil has been shown to increase the secretion of interferon gamma in lymphocytes undergoing activation (18) . Interferon gamma stimulates CXC chemokine ligand 10 and interleukin-18 (IL-18) in pancreatic islet beta cells. CXC chemokine ligand 10 also activates T cells and macrophages. IL-18 additionally enhances the expression of interferon gamma and CXC chemokine ligand 10. This mutually positive feedback loop promotes an adaptive immune reaction leading to the destruction of beta cells by infiltrating T cells through a cell-mediated mechanism (2). Furthermore, an interferon gamma-dependent JAK/STAT pathway could also cause beta cell destruction (10) . In the present case, the patient's scheduled period of rest from UFT could have led to a lower concentration of 5-fluorouracil, which would have resulted in increased interferon gamma in activated lymphocytes.
UFT might also induce the development of fulminant type 1 diabetes through increased thymidine phosphorylase levels. Thymidine phosphorylase promotes the migration of endothelial cells in vitro and promotes angiogenesis in vivo. The stimulation of angiogenesis by thymidine phosphorylase has been demonstrated in both neoplastic and non-neoplastic pathologies (19) . 5-fluorouracil has antiangiogenic effects caused by the inhibition of thymidine phosphorylase (20) . On the other hand, stressful conditions, such as hypoxia and exposure to carcinogens, stimulate the expression of thymidine phosphorylase. Inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and IL-1, which are stimulated by viral infection, are also positively associated with thymidine phosphorylase expression. In addition, thymidine phosphorylase expression enhances the expression of CXC chemokine ligand 10 (21), which may contribute to Th1 activity. In the present case, the scheduled interruption of UFT might have led to further increases in the expression of thymidine phosphorylase, leading to enhanced expression of CXC chemokine ligand 10.
In conclusion, fulminant type 1 diabetes with a rapid onset often mimics a flu-like syndrome. Therefore, clinicians should consider diabetic ketoacidosis in the differential diagnosis when examining any patient undergoing chemotherapy who presents with gastrointestinal symptoms.
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